2011 Reaxys PhD Prize opens for entries
Global competition for PhD students of chemistry
The prize will be awarded for original and innovative research in organic, organometallic and inorganic chemistry to the candidates that demonstrate excellence in methodology and approach.
Three prizewinners will each receive US$2,000 and will be invited to present their research at the Winners’ Symposium during the 14th Asian Chemical Congress, which takes place from 5–8 September in Bangkok, Thailand.
David Evans, scientific affairs director at Elsevier Properties, said: ‘The Reaxys PhD Prize celebrates innovation and creativity in chemistry research from around the world, values which lie at the heart Reaxys itself.’
He continued: ‘In 2010 we received more than 300 submissions from around the world covering the breadth of modern chemistry. The quality of research was outstanding, and the finalists and winners are clearly at the cutting edge of chemistry research. A high bar has been set for 2011.’
All entries will be evaluated by a review board of leading international chemists, chaired by the Professor A G M Barrett, Imperial College London, UK; Professor B M Trost, Stanford University, US; and Professor H N C Wong, Chinese University of Hong Kong, China, who are members of the Reaxys Advisory Board.
All submissions must include a PhD Supervisor letter of recommendation, a CV and a representative peer-reviewed piece of published research. Entries should be submitted by 28 February to the Reaxys PhD Prize website.
Elsevier Properties SA a division of scientific publisher Reed Elsevier that manages intellectual property. It owns the PharmaPendium, Beilstein and Reaxys databases.
You may also like
Research & Development
Naobios, Nuvonis and the European Vaccine Initiative collaborate to manufacture influenza challenge agent
Working with the Inno4Vac consortium, Naobios will leverage Nuvonis’s Vero Cell Bank to support the development of a controlled human infection model based on the influenza virus A(H3N2)
Research & Development
Wegovy cuts risk of heart attack, stroke or death by 57% compared with tirzepatide
Study adds to growing evidence suggesting that the heart-protective benefits seen with Wegovy are specific to the semaglutide molecule and therefore cannot be extended to other GLP-1 or GIP/GLP-1-based treatments
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Research & Development
Hamilton Health Sciences chosen for BirchBioMed burn scar treatment trial
BirchBioMed announces Hamilton Health Sciences’ (HHS) Centre for Burn Research in Ontario as the first contracted clinical trial site for its Phase II/III randomised study of the naturally based compound: FS2.
Research & Development
Indena and TCG GreenChem join forces to advance next-generation ADC technologies
Indena and TCG GreenChem are pleased to announce a new strategic collaboration aimed at accelerating the development of innovative and market-ready payload-linkers: the key component of antibody-drug conjugates (ADCs)